India’s drug development landscape is evolving, driven by successful public-private partnerships and a robust generics market, now paving the way for low- and middle-income countries (LMICs).

Tata Memorial Centre’s efforts, including collaborations with academic institutions like IIT Bombay, led to cost-effective therapies  like the CAR-T cell therapy NexCAR19, affordable for LMICs.

Countries like Indonesia and Vietnam are now exploring similar partnerships, inspired by India’s strides in developing localized pharmaceutical innovations.

Key initiatives focus on sustainable and affordable healthcare solutions tailored to LMICs, addressing diseases often overlooked by high-income countries.

Regulatory reforms and intellectual property adjustments are proposed to bolster LMIC-based drug development, prioritizing local health needs.